By Patrick Wingrove and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Nov 4 (Reuters) – Obesity drugmaker Novo Nordisk raised its 2026 outlook for the third time this year on Wednesday as quarterly sales
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
VIDEO SHOWS: ARCHIVE FOOTAGE OF REAL MADRID STADIUM SANTIAGO BERNABEU HOSTING TENNIS CLAY COURT AND…
PARIS, Nov 4 (Reuters) - Online fashion retailer Shein said on Wednesday it would invest…
By Amina Niasse and Sneha S K Nov 4 (Reuters) - CVS Health said on…
Nov 4 (Reuters) - Advanced Micro Devices rose 3% in early trading after the US…
Subscribers: Please add/update the following to the Reuters Daybook for today, Wednesday, November 4: 11…
By Howard Schneider WASHINGTON, Nov 4 (Reuters) - Democrats' sweeping midterm victory, and particularly their…